CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-19). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 680 · Search date 2026-07-19 · Methodology v0.6

Dong quai,
does it really help with Improvement of menopausal hot flashes and female hormone balance?

30-Second Summary
D
Evidence Grade D · 28 · Safety caution
Single-ingredient dong quai did not improve hot flashes or estrogenic measures in a direct clinical trial
What the
research shows
The claim that single-ingredient dong quai improves menopausal hot flashes or hormone balance is rated D. In a 24-week randomized double-blind trial of 71 postmenopausal women, hot flashes, the Kupperman index, endometrial thickness, and vaginal maturation did not differ from placebo, providing direct null evidence. There is no independent replication in the same indication, however; the 22-person trial involved men, and the guideline derives from the same women's trial, so neither establishes repeated refutation for an F grade.
What the
ads claim
Marketing turns female ginseng, estrogen balance, circulation, and traditional use into a hormone effect from a single capsule. The direct trial supported neither an estrogen-like response nor relief of menopausal symptoms.
*

Useful facts when choosing a product

  • This verdict concerns single-ingredient Angelica sinensis capsules and is distinct from verdict 53 on EstroG and verdict 505 on the multi-herb HemoHIM product containing Korean angelica.
  • Chinese, Korean, Japanese, and other Angelica species differ botanically and chemically, so evidence cannot be exchanged on the basis of a shared common name.
  • Photosensitivity has been raised for compounds in Angelica products, and anticoagulant overlap is a concern; a case report described a marked INR increase with concurrent warfarin.
  • Use during pregnancy should be avoided because of possible uterine activity and inadequate safety data, and use should be disclosed before surgery or with anticoagulant or antiplatelet medicines.
Gap Measurement · Verdict 680 · D 28
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Hirata et al. randomized 71 women with menopausal-range FSH and hot flashes to dong quai or placebo for 24 weeks. Neither hot-flash diaries and the Kupperman index nor vaginal maturation and ultrasound endometrial thickness differed between groups. A three-month pilot trial by Al-Bareeq et al. in 22 men likewise failed to improve hot-flash duration or severity. The Endocrine Society guideline advises counseling about the lack of consistent benefit from complementary approaches including dong quai.

02

Why this is classified as D (28)

D. A 24-week single-ingredient trial in 71 postmenopausal women found hot-flash, Kupperman, endometrial, and vaginal-maturation outcomes identical to placebo, but no independent replication exists in the same indication. The 22-person men's trial addresses a different population and the guideline relies on the same women's trial, so the evidence falls short of repeated refutation and yields D with 28 points. Photosensitivity, anticoagulant interaction, and possible uterine contractions remain independent safety issues.

Counterpoint. When menopausal hot flashes impair sleep or daily function, individualized hormone therapy or evidence-based nonhormonal prescriptions can be discussed. Traditional circulation or menstrual uses are separate from this single-ingredient menopause verdict.

Rejudgment record. Reassessment (cross-check reflected) — Applied D because a 24-week randomized double-blind placebo-controlled trial of single-ingredient Angelica sinensis in 71 postmenopausal women found directly null hot-flash, Kupperman-index, endometrial-thickness, and vaginal-maturation outcomes, but there is no independent same-indication replication and the men's trial and guideline do not establish repeated refutation

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improvement of menopausal hot flashes and female hormone balanceDA 71-person single-ingredient randomized trial found a direct null result versus placebo.
Whether independent repeated refutation exists?Only one small direct trial exists, with no independent replication, so the evidence does not meet the F threshold.
Attribution of multi-ingredient women's-product imagery to dong quai alone?Imagery from multi-ingredient products cannot be attributed to dong quai alone.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Randomized double-blind placebo-controlled trial24Supported by the Kaiser Foundation Hospitals community-service programHot flashes, Kupperman index, endometrial thickness, and vaginal maturation indexNo symptom or estrogenic outcome significantly differed between dong quai and placebo.Key direct refuting randomized trial
Study 2Randomized double-blind placebo-controlled pilot trial3No conflicts or external funding were reportedHot-flash frequency, duration, and severityNo benefit was found for hot-flash duration or severity.Repeated null evidence in an indirect population
Study 3GRADE-based clinical guideline and evidence review3Endocrine SocietyTreatment of menopausal vasomotor symptomsRecommended counseling about the lack of consistent benefit from complementary therapies including dong quai.Guideline context consistent with the direct trial
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-19).

Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997;68(6):981-986. PMID: 9418683. DOI: 10.1016/S0015-0282(97)00397-X.
checked
Al-Bareeq RJ, Ray AA, Nott L, Pautler SE, Razvi H. Dong Quai (Angelica sinensis) in the treatment of hot flashes for men on androgen deprivation therapy: results of a randomized double-blind placebo controlled trial. Can Urol Assoc J. 2010;4(1):49-53. PMID: 20165579. PMCID: PMC2811999. DOI: 10.5489/cuaj.775.
checked
Page RL 2nd, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy. 1999;19(7):870-876. PMID: 10417036. DOI: 10.1592/phco.19.10.870.31558.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none

Cite this verdict

Dong quai x menopausal hot flashes and female hormone balance Evidence Grade D card
[Chamgap] Dong quai x menopausal hot flashes and female hormone balance — Evidence Grade D·28. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/dong-quai-menopause-hot-flashes-hormone-balance/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.